How it works, simply
It blocks a calcium channel involved in pain signaling in the spinal cord.
What the evidence tells us
It is delivered into spinal fluid under specialist care, not through a routine subcutaneous vial protocol.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Severe psychiatric and neurological effects are described in the boxed warning.
- It is contraindicated in people with a history of psychosis.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Blocks N-type voltage-sensitive calcium channels in the spinal cord.
Sponsor or developer: TerSera Therapeutics
Studied or labeled topics: Severe chronic pain
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: PRIALT prescribing information ↗ · Regulator · Sep 30, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.